CN107266568A - 抗foxp3蛋白单克隆抗体及其用途 - Google Patents
抗foxp3蛋白单克隆抗体及其用途 Download PDFInfo
- Publication number
- CN107266568A CN107266568A CN201710545662.0A CN201710545662A CN107266568A CN 107266568 A CN107266568 A CN 107266568A CN 201710545662 A CN201710545662 A CN 201710545662A CN 107266568 A CN107266568 A CN 107266568A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- foxp3
- umab248
- albumen
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100027581 Forkhead box protein P3 Human genes 0.000 title claims abstract description 50
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 title claims abstract description 50
- 238000001514 detection method Methods 0.000 claims abstract description 12
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 17
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 230000003053 immunization Effects 0.000 abstract description 4
- 230000002055 immunohistochemical effect Effects 0.000 abstract description 3
- 238000002649 immunization Methods 0.000 abstract description 2
- 230000037029 cross reaction Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010048999 Transcription Factor 3 Proteins 0.000 description 1
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及生物技术领域,公开了一种杂交瘤细胞株(保藏编号为CGMCC No.13823),以及由此杂交瘤细胞株产生的单克隆抗体UMAB248。本发明还涉及单克隆抗体UMAB248在制备用于检测FOXP3蛋白的免疫检测工具中的应用,含单克隆抗体UMAB248的免疫组化试剂盒,以及单克隆抗体UMAB248在制备用于标记肿瘤的试剂盒中的应用。本发明所述单克隆抗体可与FOXP3蛋白特异性结合,而与细胞内其他蛋白无交叉反应,显著提高了FOXP3蛋白免疫检测的特异性、准确性和可靠性。
Description
技术领域
本发明涉及生物技术领域,具体涉及可特异结合FOXP3蛋白的单克隆抗体UMAB248、产生所述单克隆抗体的细胞株及应用该抗体用于诊断的方法和用途。
背景技术
叉头样转录因子3(fork head box protein 3,FOXP3)是脊椎动物叉头样转录因子家族中的一员,由Brunkow等在2001年首次报道。于2003年被证实为CD4+CD25+调节性T细胞(regulatory T cell,Treg)的特异性标志。高表达于免疫系统中“主动”机制(由一群功能上起抑制作用的细胞介导的耐受机制)的CD4+CD25+Treg细胞中,FOXP3+CD4+CD25+Treg细胞在肿瘤免疫逃逸机制中发挥作用,并先后在黑素瘤、胰腺癌、胃癌、肝癌、乳腺癌、肺癌等肿瘤中检测到FOXP3的高表达。并有研究证实,FOXP3表达的高低可作为评价治疗效果和有无复发转移的一个很有意义的指标。
临床上常用免疫组织化学(IHC)病理实验检测肿瘤细胞中蛋白的表达状况,然而IHC实验的核心为特异性结合蛋白的单克隆抗体,其性能的优劣直接决定着整个检测的灵敏度和特异性。因此,研制出一种结合特异性较高的针对FOXP3蛋白的单克隆抗体对IHC检测FOXP3表达水平具有重要的意义。
发明内容
有鉴于此,本发明的目的在于提供一种结合特异性较高的FOXP3蛋白的单克隆抗体,及其在制备用于检测FOXP3蛋白的免疫检测工具中的应用。
本发明提供了一种杂交瘤细胞株,保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称为CGMCC),保藏日期为2017年4月6日,保藏编号为CGMCC No.13823。
本发明还提供了一种特异性结合FOXP3蛋白的单克隆抗体UMAB248,由上述杂交瘤细胞株产生。
本发明所述单克隆抗体的制备方法如下:
(1)重组表达载体的构建:根据FOXP3 ORF核苷酸序列(FOXP3 ORF核苷酸序列如SEQ ID NO.1所示,1296bp;FOXP3氨基酸序列如SEQ ID NO.2所示)
设计引物PCR扩增FOXP3 ORF第1bp位到第1296bp位序列,基因两侧分别引入限制性内切酶位点SgfI和MluI,插入表达载体pET23a-N-His,构建FOXP3氨基酸序列第1位到第431位的重组表达质粒pET23a-rFOXP3;上游扩增引物序列,SEQ ID NO.3:CACGCGATCGCATGCCCAACCCCAGGCCTG下游扩增引物序列SEQ ID NO.4:ACCGACGCGTTCAGGGGCCAGGTGTAGGGT
(2)FOXP3重组蛋白的表达与纯化:将FOXP3重组表达质粒转化E.Coli细胞,裂解离心获得上清,镍柱亲和层析柱纯化,获得纯化的FOXP3重组蛋白;
(3)单克隆抗体的筛选与制备:采用上述纯化的FOXP3重组蛋白免疫Balb/c小鼠,取小鼠脾脏细胞与SP2/0细胞进行融合,有限稀释法获得单克隆,ELISA法筛选阳性杂交瘤细胞,获得能分泌抗FOXP3特异性抗体的杂交瘤细胞株,命名为UMAB248,亚型鉴定为IgG1;通过无血清培养基制备抗体,通过亲和层析柱纯化获得FOXP3单克隆抗体UMAB248。分别通过Western Blot、免疫组化实验验证该单克隆抗体的灵敏度和特异性。
本发明还提供了单克隆抗体UMAB248在制备用于检测FOXP3蛋白的免疫检测工具中的应用。
具体地,所述免疫检测工具为试剂盒、芯片或试纸。
在具体的实施例中,本发明提供了一种免疫组化检测试剂盒,包括上述单克隆抗体UMAB248,可检测组织细胞中FOXP3的表达状况。
本发明还提供了上述单克隆抗体在制备用于标记肿瘤的试剂盒中的应用。其中所述肿瘤具体是指肿瘤细胞的增殖与FOXP3的表达密切相关的肿瘤,包括但不限于黑素瘤、胰腺癌、胃癌、肝癌、乳腺癌、肺癌。
与现有技术相比,本发明提供了一种杂交瘤细胞株(保藏编号为CGMCCNo.13823),以及由此杂交瘤细胞株产生的单克隆抗体UMAB248。本发明还提供了单克隆抗体UMAB248在制备用于检测FOXP3蛋白的免疫检测工具中的应用,含单克隆抗体UMAB248的免疫组化试剂盒,以及单克隆抗体UMAB248在制备用于标记肿瘤的试剂盒中的应用。本发明所述单克隆抗体可与FOXP3蛋白特异性结合,真实反映肿瘤细胞内FOXP3蛋白表达水平,可应用于黑素瘤、胰腺癌、胃癌、肝癌、乳腺癌、肺癌FOXP3蛋白表达水平的检测。
保藏信息
用于保藏的杂交瘤细胞株UMAB248的分类命名为:鼠抗人叉头框蛋白P3(FOXP3)单克隆杂交瘤细胞株;
保藏单位全称:中国微生物菌种保藏管理委员会普通微生物中心;
保藏单位简称:CGMCC;
保藏单位地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所;
保藏日期:2017年4月6日;
保藏编号:CGMCC No.13823。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示实施例1克隆位点设计如图,其中底纹部分为ORF区;
图2——图8示实施例4福尔马林固定、石蜡包埋的乳腺、结肠、胃癌、肝癌、肺、淋巴、黑色素瘤组织免疫组化结果图(一抗为FOXP3单克隆抗体UMAB248);
图9示实施例5 OriGene蛋白芯片鉴定结果图(一抗为FOXP3单抗UMAB248,1:100;二抗为DyLight649-conjugated AffiniPure Fragment Goat-anti-Mouse IgG,1:400)。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1、FOXP3重组表达质粒的构建
以从美国傲锐东源生物科技有限公司获得的质粒RC217580(含FOXP3ORF 4080bp)为模板,设计两条引物并分别引入酶切位点SgfI和MluI,克隆入表达载体pET23a-N-His,建立FOXP3重组表达质粒。克隆位点设计如图1所示。
实施例2、FOXP3重组蛋白的表达与纯化
1、转化E.coli细胞:将100ul感受态细胞置于冰上融化后加入质粒DNA轻混匀,冰浴30min后42℃热激90s,然后将其继续冰浴1-2min。在超净台内加入500ul新鲜无抗LB培养基,于37℃摇床孵育45min后取适量菌液均匀涂布于含抗生素的平板上,将培养皿倒置于37℃恒温培养箱中培养过夜。
2、裂解细胞:挑取单克隆于新鲜培养基中,37℃、200rpm培养至OD值达到0.4~0.6时加入IPTG(终浓度1mM)诱导培养7h。离心收集菌体,然后用裂解缓冲液重悬菌体,超声破碎20min后于4℃下12000rpm离心20min,收集上清。取少量上清蛋白用anti-His抗体做WB鉴定。
3、镍柱亲和层析柱纯化:用缓冲液平衡镍柱,将上清用0.45μm滤膜过滤后上样并收集流出,用缓冲液淋洗去除未结合的蛋白,最后用含不同浓度咪唑的洗脱液洗脱,分别收集后进行SDS-PAGE鉴定,将符合要求的洗脱蛋白合并加入10%甘油,纯化后的重组FOXP3蛋白用SDS-PAGE鉴定。
实施例3、FOXP3单克隆抗体的制备与筛选
根据标准方法用重组产生的纯化的FOXP3蛋白片段用于对Balb/c小鼠(北京维通利华实验动物技术有限公司)进行免疫。具体方法如下:
1、动物免疫:经过纯化的FOXP3抗原以完全弗氏佐剂乳化,采用皮下或腹腔注射方法免疫6-8周龄Balb/c小鼠,免疫剂量为50μg/只,间隔两周后进行第二次免疫,以不完全弗氏佐剂乳化,免疫剂量为50μg/只。免疫两次后取尾血以ELISA法梯度稀释测定血清效价;根据结果确定是否加强免疫,选取抗体效价最高的小鼠进行细胞融合。
2、细胞融合:骨髓瘤细胞采用Balb/c来源的sp2/0,融合时处于对数生长期;取已免疫小鼠脾脏,制成淋巴细胞单细胞悬液;小鼠脾淋巴细胞与骨髓瘤细胞以1:5-1:10混合,滴加37℃的50%PEG(PH 8.0)1mL,加入不完全培养基及其余终止液,离心弃上清后加入HAT培养基悬浮混匀,MC定容到50mL,分装到3.5cm培养皿中,放于湿盒中,置于37℃、5%CO2恒温培养箱中进行培养。
3、筛选和克隆:融合7-10天内挑选细胞克隆,使用FOXP3纯化重组蛋白进行ELISA测试。标记细胞株号。对阳性孔细胞进行有限稀释,每次有限稀释后5-6天测定ELISA值,挑取OD280阳性值较高的单克隆孔进行有限稀释,直至ELISA测定96孔板全板结果为阳性。挑取阳性值高的单克隆定株。其对应融合板细胞株为UMAB248。
4、腹水单抗的制备与纯化:10-12周龄的雄性Balb/c小鼠腹腔注射0.5ml降植烷,一周后每只小鼠用1mL注射器腹腔注射经PBS洗涤重悬的单克隆细胞悬液,细胞用量为5×106/只,每株抗体打2只小鼠。待小鼠腹水积聚后收集腹水,离心取上清,亲和层析法进行腹水纯化,根据抗体亚型选择相应柱料,细胞株UMAB248产生的单抗为IgG1,采用protein G进行纯化。纯化后的单抗浓度测定、WB检测、分装、冻存在-20℃。
实施例4、单克隆抗体UMAB248为一抗的免疫组化检测
(1)、实验方法:
1、取福尔马林固定的人淋巴结组织与人扁桃体组织块进行石蜡包埋,使用Finesse组织切片机进行切片,组织厚度为6μm。
2、脱蜡与水化:分析纯二甲苯3×10min,无水乙醇3×10min,95%乙醇5min,85%乙醇5min,75%乙醇5min,去离子水浸泡3min×3次
3、加入抗原修复液(0.01M,pH6.0枸橼酸钠缓冲液)高压锅高压热修复3min,待高压锅温度降至约90℃时,打开高压锅,取出标本,然后自然冷却至室温。去离子水浸泡3min×3次。
4、使用3%过氧化氢灭活组织内源性过氧化物酶,室温静置10min。去离子水浸泡5min×3次。
5、加上封闭液(PBS+5%脱脂奶粉+5%正常山羊血清),37℃孵育60min。
6、去除封闭液,勿冲洗,加入FOXP3单抗(UMAB248),稀释比:1:150,使用封闭液进行稀释。置于湿盒中,37℃孵育60min。PBST(0.1%Tween-20)洗涤2次,每次洗涤5min。PBST(0.02%Tween-20)洗涤1次,每次洗涤5min。
7、滴加Polink-试剂盒2(Catlog No.D37-15)试剂1,37℃孵育10-20分钟。使用PBS洗涤3次,每次5min。滴加Polink-2试剂盒(Catlog No.D37-15)试剂2,37℃孵育10-20分钟,使用PBS洗涤3次,每次5min。
8、应用DAB溶液(中杉金桥ZLI-9019)显色,显色3~10min。蒸馏水洗涤。
9、苏木精复染细胞核2min,蒸馏水漂洗,1%盐酸分化。蒸馏水漂洗3次,室温静置1min。
10、脱水和透明:75%乙醇5min,100%乙醇5min x 3次,85%乙醇5min,95%乙醇5min,100%乙醇3×5min;二甲苯3×5min,中性树胶封片。
11、镜检,见图2-7。
(2)、实验结果:
由图2——图8结果可见,在乳腺、结肠、胃癌、肝癌、肺、淋巴、黑色素瘤组织中可见到一些浸润淋巴细胞的特异性胞核染色。结果与FOXP3在细胞内的定位及组织表达特异性一致,表明单克隆抗体UMAB248可用于免疫组织化学检测FOXP3蛋白的水平。
实施例5、单克隆抗体UMAB248的特异性检测
OriGene高密度蛋白芯片上包含10,000个HEK293T细胞蛋白过表达裂解物,每种蛋白裂解液在芯片上具有两个拷贝的重复。蛋白裂解液被印迹在硝酸纤维素膜上。每一钟蛋白裂解液的定位可以通过Excel文件进行准确定位。蛋白芯片上蛋白分为40个亚矩阵,每个亚矩阵上有一些参照,通过参照,可以定量每个芯片点上蛋白的含量,监控每次免疫反应数据的重复性,以及定位阳性信号的方向。以下为使用OriGene蛋白(OriGene Cat PA100001)芯片进行UMAB248抗体鉴定实验的实验方法:
1、将一张蛋白芯片放在50mL离心管中,使用40mL去离子水浸润芯片,置于摇床上,室温混合30分钟。弃掉去离子水,使用10mLPBST平衡芯片。室温处理10分钟。
2、向50mL离心管中加入40mL5%脱脂牛奶(用PBST进行稀释)置于摇床上,室温封闭30分钟。
3、使用封闭液(5%脱脂牛奶)稀释一抗UMAB248,稀释比列为1:100。
4、将洁净的封口膜粘贴到实验台上,滴加250-300μL一抗在封口膜上。
5、将蛋白芯片从封闭液中抽出,将蛋白芯片NC膜的一面朝下,从芯片的一边接触抗体,慢慢滑下,依靠液体表面张力,抗体将慢慢浸润芯片NC膜,直至整张NC膜浸润在一抗溶液中。整个操作过程避免产生气泡。将芯片移到4℃环境下,静置,一抗孵育过夜。在芯片上加盖培养皿盖,其上黏附一张湿纸巾,以防止长时间孵育导致抗体蒸发。
6、第二天将芯片移至50mL离心管中,使用PBST漂洗芯片两次,去除多余的抗体。使用40mL PBST(0.1%Tween-20)洗涤芯片,置于摇床上混合均匀,洗涤三次,每次洗涤5min。
7、使用封闭液(5%脱脂牛奶)稀释二抗DyLight649-conjugated AffiniPureFragment Goat-anti-Mouse IgG,稀释比例为1:400。
8、按照上述步骤4,步骤5进行二抗孵育操作。室温孵育1小时。在芯片上方用铝箔纸遮盖,以防止发生信号漂白。
9、按照上述步骤6,使用PBST洗涤芯片。
10、使用去离子水冲洗芯片,以去除残余的盐分和变性剂。
11、室温干燥芯片,确保芯片完全干燥。
12、使用芯片扫描仪读取荧光信号。
13、根据BSA-Cy3以及BSA-Cy5确定芯片方向以及阳性信号的位点。
14、根据阳性信号位点找出对应蛋白裂解液ID,根据裂解液数据库信息,查找到对应蛋白名称,NCBI录入号(accession number),蛋白ID,蛋白大小等信息。
结果如图9所示,单抗UMAB248在OriGene蛋白芯片上能特异地识别FOXP3蛋白,表明单抗UMAB248的特异性较好。
SEQUENCE LISTING
<110>无锡傲锐东源生物科技有限公司
<120>抗FOXP3蛋白单克隆抗体及其用途
<210> 1
<211>2961
<212> DNA
<213>人工序列
<400> 1
ORIGIN
1 ATGCCCAACC CCAGGCCTGG CAAGCCCTCG GCCCCTTCCT TGGCCCTTGG CCCATCCCCA
61 GGAGCCTCGC CCAGCTGGAG GGCTGCACCC AAAGCCTCAG ACCTGCTGGG GGCCCGGGGC
121 CCAGGGGGAA CCTTCCAGGG CCGAGATCTT CGAGGCGGGG CCCATGCCTC CTCTTCTTCC
181 TTGAACCCCA TGCCACCATC GCAGCTGCAG CTGCCCACAC TGCCCCTAGT CATGGTGGCA
241 CCCTCCGGGG CACGGCTGGG CCCCTTGCCC CACTTACAGG CACTCCTCCA GGACAGGCCA
301 CATTTCATGC ACCAGCTCTC AACGGTGGAT GCCCACGCCC GGACCCCTGT GCTGCAGGTG
361 CACCCCCTGG AGAGCCCAGC CATGATCAGC CTCACACCAC CCACCACCGC CACTGGGGTC
421 TTCTCCCTCA AGGCCCGGCC TGGCCTCCCA CCTGGGATCA ACGTGGCCAG CCTGGAATGG
481 GTGTCCAGGG AGCCGGCACT GCTCTGCACC TTCCCAAATC CCAGTGCACC CAGGAAGGAC
541 AGCACCCTTT CGGCTGTGCC CCAGAGCTCC TACCCACTGC TGGCAAATGG TGTCTGCAAG
601 TGGCCCGGAT GTGAGAAGGT CTTCGAAGAG CCAGAGGACT TCCTCAAGCA CTGCCAGGCG
661 GACCATCTTC TGGATGAGAA GGGCAGGGCA CAATGTCTCC TCCAGAGAGA GATGGTACAG
721 TCTCTGGAGC AGCAGCTGGT GCTGGAGAAG GAGAAGCTGA GTGCCATGCA GGCCCACCTG
781 GCTGGGAAAA TGGCACTGAC CAAGGCTTCA TCTGTGGCAT CATCCGACAA GGGCTCCTGC
841 TGCATCGTAG CTGCTGGCAG CCAAGGCCCT GTCGTCCCAG CCTGGTCTGG CCCCCGGGAG
901 GCCCCTGACA GCCTGTTTGC TGTCCGGAGG CACCTGTGGG GTAGCCATGG AAACAGCACA
961 TTCCCAGAGT TCCTCCACAA CATGGACTAC TTCAAGTTCC ACAACATGCG ACCCCCTTTC
1021 ACCTACGCCA CGCTCATCCG CTGGGCCATC CTGGAGGCTC CAGAGAAGCA GCGGACACTC
1081 AATGAGATCT ACCACTGGTT CACACGCATG TTTGCCTTCT TCAGAAACCA TCCTGCCACC
1141 TGGAAGAACG CCATCCGCCA CAACCTGAGT CTGCACAAGT GCTTTGTGCG GGTGGAGAGC
1201 GAGAAGGGGG CTGTGTGGAC CGTGGATGAG CTGGAGTTCC GCAAGAAACG GAGCCAGAGG
1261 CCCAGCAGGT GTTCCAACCC TACACCTGGC CCCTGA
//
<210> 2
<211>986
<212> PRT
<213>人工序列
<400> 2
ORIGIN
1 MPNPRPGKPS APSLALGPSP GASPSWRAAP KASDLLGARG PGGTFQGRDL RGGAHASSSS
61 LNPMPPSQLQ LPTLPLVMVA PSGARLGPLP HLQALLQDRP HFMHQLSTVD AHARTPVLQV
121 HPLESPAMIS LTPPTTATGV FSLKARPGLP PGINVASLEW VSREPALLCT FPNPSAPRKD
181 STLSAVPQSS YPLLANGVCK WPGCEKVFEE PEDFLKHCQA DHLLDEKGRA QCLLQREMVQ
241 SLEQQLVLEK EKLSAMQAHL AGKMALTKAS SVASSDKGSC CIVAAGSQGP VVPAWSGPRE
301 APDSLFAVRR HLWGSHGNST FPEFLHNMDY FKFHNMRPPF TYATLIRWAI LEAPEKQRTL
361 NEIYHWFTRM FAFFRNHPAT WKNAIRHNLS LHKCFVRVES EKGAVWTVDE LEFRKKRSQR
421 PSRCSNPTPG P
Claims (7)
1.一种特异性结合FOXP3蛋白的单克隆抗体UMAB248,由保藏编号为CGMCC No.13823的杂交瘤细胞株产生。
2.一种杂交瘤细胞株,其保藏编号为CGMCC No.13823。
3.如权利要求1所述的单克隆抗体在制备用于检测FOXP3蛋白的免疫检测工具中的应用。
4.根据权利要求3所述的应用,所述免疫检测工具为试剂盒、芯片或试纸。
5.一种免疫组化检测试剂盒,包括权利要求1所述的单克隆抗体。
6.如权利要求1所述的单克隆抗体在制备用于标记组织细胞的试剂盒中的应用。
7.根据权利要求6所述的应用,所述组织细胞为黑素瘤、胰腺癌、胃癌、肝癌、乳腺癌、肺癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710545662.0A CN107266568A (zh) | 2017-07-07 | 2017-07-07 | 抗foxp3蛋白单克隆抗体及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710545662.0A CN107266568A (zh) | 2017-07-07 | 2017-07-07 | 抗foxp3蛋白单克隆抗体及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107266568A true CN107266568A (zh) | 2017-10-20 |
Family
ID=60072221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710545662.0A Pending CN107266568A (zh) | 2017-07-07 | 2017-07-07 | 抗foxp3蛋白单克隆抗体及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107266568A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103290020A (zh) * | 2013-04-11 | 2013-09-11 | 广东海大畜牧兽医研究院有限公司 | 抗猪Foxp3蛋白的单克隆抗体、多克隆抗体及应用 |
| CN103946238A (zh) * | 2011-08-23 | 2014-07-23 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
-
2017
- 2017-07-07 CN CN201710545662.0A patent/CN107266568A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103946238A (zh) * | 2011-08-23 | 2014-07-23 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
| CN103290020A (zh) * | 2013-04-11 | 2013-09-11 | 广东海大畜牧兽医研究院有限公司 | 抗猪Foxp3蛋白的单克隆抗体、多克隆抗体及应用 |
Non-Patent Citations (3)
| Title |
|---|
| BIOLEGEND: "《Purified anti-human FOXP3 Antibody》", 13 December 2016, BIOLEGEND * |
| EMD MILLIPORE CORPORATION: "《Anti-Foxp3 (mouse), APC, clone 3G3 Monoclonal Antibody》", 31 December 2013, EMD MILLIPORE CORPORATION * |
| 刘灵: "FOXP3对Ⅳ期结直肠癌化疗及预后影响的相关性研究", 《中国优秀硕士学位论文全文数据库(电子期刊)医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107188962A (zh) | 抗ck7蛋白单克隆抗体及其用途 | |
| CN106978400A (zh) | 抗pd‑l1蛋白单克隆抗体及其用途 | |
| CN105131114B (zh) | 抗p16蛋白单克隆抗体杂交瘤细胞及其产生的抗p16单克隆抗体和应用 | |
| CN102827281B (zh) | 抗cd2蛋白单克隆抗体及其用途 | |
| CN105254759A (zh) | 抗cd56蛋白单克隆抗体杂交瘤细胞及其产生的抗cd56单克隆抗体和应用 | |
| CN108997496A (zh) | 抗gfap蛋白单克隆抗体及其用途 | |
| CN106188292B (zh) | 抗cd4蛋白单克隆抗体及其用途 | |
| CN106957823A (zh) | 抗pd‑l2蛋白单克隆抗体及其用途 | |
| CN107188965A (zh) | 抗dog1蛋白单克隆抗体及其用途 | |
| CN107446046A (zh) | 抗cd20蛋白单克隆抗体及其用途 | |
| CN106854245A (zh) | 抗cd30蛋白单克隆抗体及其用途 | |
| CN108997501A (zh) | 抗vwf蛋白单克隆抗体及其用途 | |
| CN105158478A (zh) | 一种人乳铁蛋白双抗夹心酶联免疫检测试剂盒 | |
| CN109096400A (zh) | 抗pdpn蛋白单克隆抗体及其用途 | |
| CN109021102A (zh) | 抗sma蛋白单克隆抗体及其用途 | |
| CN108998423A (zh) | 抗波形蛋白(Vimentin)单克隆抗体及其用途 | |
| CN106749668A (zh) | 抗ido1蛋白单克隆抗体及其用途 | |
| CN107236040A (zh) | 抗msh6蛋白单克隆抗体及其用途 | |
| CN109021101A (zh) | 抗pax8蛋白单克隆抗体及其用途 | |
| CN106977605A (zh) | 抗cd19蛋白单克隆抗体及其用途 | |
| CN105274060B (zh) | 抗gata3蛋白单克隆抗体杂交瘤细胞及其产生的抗gata3单克隆抗体和应用 | |
| CN110357964A (zh) | 抗cd31蛋白单克隆抗体及其用途 | |
| CN107266568A (zh) | 抗foxp3蛋白单克隆抗体及其用途 | |
| CN107058238A (zh) | 抗cd10蛋白单克隆抗体及其用途 | |
| CN107266572A (zh) | 抗pd‑l1蛋白单克隆抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171020 |